

Seeking Novel Animal Models of COPD Pathophysiology

Daiichi Sankyo, a global pharmaceutical company, is seeking research related to **novel animal models of chronic obstructive pulmonary disease (COPD)**, specifically models of **type 2 COPD, asthma-COPD overlap, and COPD exacerbations**.



Approaches of Interest:

- Models capturing **type 2 inflammation, neutrophilic inflammation, and emphysematous changes** are sought, with impaired **oxidative stress responses** reproduced at the gene or protein level
- Models should demonstrate a clear **advantage over standard cigarette smoke exposure and elastase-induced models**, such as more human-like pathology or a faster disease onset
- Any species or model system with demonstrated translatability is of interest, including human-cell-reconstituted or immunodeficient mice, as well as *in vitro* systems such as organoids, precision-cut lung slices, and organ-on-chip platforms
- Exacerbation models triggered by any clinically relevant stimulus are also of interest
- Non-type 2 COPD subtypes will be considered where translatability exceeds that of conventional cigarette smoke or elastase models

Out of Scope:

- Research without supporting data

Developmental Stages of Interest

- Basic and preclinical research stages are within scope
- **Submissions must include model characteristics, development protocol, *in vivo* data, and readouts. Positive-control validation is welcomed**

Submission Information

Daiichi Sankyo invites applications from both academic institutions and industry organizations and welcomes proposals based on both existing technologies or methods and novel approaches. Applicants should complete the **submission form** which should contain a brief, non-confidential overview of your proposal, demonstrating how the RFP requirements are satisfied by your approach. To submit your proposal, please visit our **website**, register, and submit your application form under the appropriate Connect campaign

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Company profiles
-  Technologies
-  Research projects

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **21st September 2026 - 10:59 pm GMT**

Have any questions?

Contact our team at campaigns@inpart.io

